IQVIA (NYSE:IQV) Receives “Outperform” Rating from Royal Bank of Canada

Royal Bank of Canada reaffirmed their outperform rating on shares of IQVIA (NYSE:IQV) in a research report sent to investors on Monday,Benzinga reports. The firm currently has a $270.00 price objective on the medical research company’s stock.

A number of other research firms have also recently commented on IQV. Bank of America reduced their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. JPMorgan Chase & Co. decreased their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. TD Cowen cut their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Barclays decreased their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Finally, Stifel Nicolaus cut their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $252.50.

IQVIA Stock Down 0.7 %

NYSE:IQV opened at $206.67 on Monday. The firm has a market capitalization of $37.51 billion, a price-to-earnings ratio of 27.56, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The stock’s 50 day moving average price is $200.67 and its two-hundred day moving average price is $219.27.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts expect that IQVIA will post 10.81 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director John G. Danhakl acquired 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the transaction, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 1.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On IQVIA

A number of institutional investors have recently modified their holdings of IQV. Capital Performance Advisors LLP bought a new position in IQVIA in the third quarter valued at about $27,000. Synergy Asset Management LLC acquired a new position in IQVIA during the 4th quarter worth approximately $33,000. Avior Wealth Management LLC lifted its stake in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. boosted its position in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares in the last quarter. Finally, UMB Bank n.a. grew its stake in shares of IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after buying an additional 99 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.